Want to see PTGX full AI Analyst Report?

Protagonist Therapeutics (PTGX) Price & Analysis

743 Followers

PTGX Stock Chart & Stats

$105.98

-$0.87(-2.26%)

At close: Jan 08 4:00 PM EST

$105.98

-$0.87(-2.26%)

Day’s Range― - ―

52-Week Range$50.49 - $141.10

Previous CloseN/A

Volume120.35K

Average Volume (3M)833.86K

Market Cap

$9.06B

Enterprise Value$6.89K

Total Cash (Recent Filing)$547.79M

Total Debt (Recent Filing)$9.78M

Price to Earnings (P/E)―

Beta0.01

Next Earnings

Jul 30, 2026

EPS Estimate

2.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.80

Shares Outstanding64,311,370

10 Day Avg. Volume856,062

30 Day Avg. Volume833,857

Financial Highlights & Ratios

PEG Ratio0.29

Price to Book (P/B)9.03

Price to Sales (P/S)120.66

P/FCF Ratio99.01

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$125.00

Price Target Upside17.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)4.25

Revenue Forecast (FY)$523.09M

Bulls Say, Bears Say

Bulls Say

Low Leverage And Substantial EquityThe company's conservative capital structure and sizable equity provide durable financing flexibility to fund R&D and absorb operational volatility. Low leverage reduces refinancing and interest risk, supporting multi‑quarter development plans and strategic optionality without immediate capital markets pressure.

High Gross Margins With Revenue AccelerationSustained ~99% gross margins reflect a scalable biotech revenue model where incremental revenue converts strongly to gross profit. Coupled with material revenue acceleration, this suggests collaboration and licensing income can provide high-margin cash inflows that, if sustained, materially improve long‑term cash deployment and reinvestment capacity.

Governance Continuity And Incentive AlignmentRecent shareholder approvals reinforced board continuity, auditor ratification, and adoption of an equity incentive plan, supporting stable oversight and long‑term employee alignment. Strong governance continuity and incentive tools help retain scientific and executive talent critical for multi‑year clinical programs.

Bears Say

Renewed Negative Operating Cash FlowThe sharp TTM cash burn increases reliance on the balance sheet or external financing to sustain operations and trials. Persistent negative operating and free cash flow can force dilution, slow programs, or require partnership exits, raising execution risk over the next several quarters if cash burn is not controlled or new funding secured.

Deep Operating Losses And Volatile ProfitabilitySevere negative margins and volatile year‑to‑year profitability limit the firm's ability to self‑fund development and depress returns on equity (ROE negative TTM). Until clinical success or sustained partner revenue occurs, profitability volatility undermines long‑term earnings visibility and increases investor and partner scrutiny.

Revenue Dependent On Collaborations And FinancingThe business model relies on upfronts, milestones, and partner R&D reimbursements rather than product sales, creating revenue timing and contingency risk. This dependency plus intermittent milestone receipts increases financing unpredictability and heightens sensitivity to partner decisions and regulatory outcomes over multiple quarters.

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $165 from $137 at Citizens

Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $165 from $137 and keeps an Outperform...

5d ago

PTGX

Protagonist Therapeutics price target raised to $151 from $119 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $151 from $119 and keeps an Overweight...

8d ago

PTGX

Protagonist Therapeutics price target raised to $145 from $121 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy...

14d ago

JNJ

PTGX

Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating

Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Protagonist Therapeutics. The associated price target...

6h ago

PTGX

Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan

Protagonist Therapeutics ( ($PTGX) ) has shared an announcement. At its recent Annual Meeting, Protagonist Therapeutics’ stockholders elected...

1M ago

PTGX

Protagonist Therapeutics price target raised to $130 from $125 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy...

2M ago

PTGX

Protagonist Therapeutics price target raised to $137 from $120 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and...

3M ago

PTGX

Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $97 and keeps a...

3M ago

PTGX

Protagonist Therapeutics management to meet virtually with Clear Street

Virtual Meeting to be held on May 12-13 hosted by Clear Street. Published first on TheFly – the...

3M ago

PTGX

Protagonist Therapeutics participates in a conference call with JPMorgan

Conference call with management will be held on May 6 at 2 pm hosted by JPMorgan.Webcast Link Published...

3M ago

PTGX

Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide

Protagonist Therapeutics (PTGX) announced that it has exercised its right to opt out of the 50:50 U.S. profit...

3M ago

TAK

PTGX

Protagonist Therapeutics price target raised to $121 from $110 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and...

3M ago

JNJ

PTGX

Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target

Protagonist Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Srikripa Devarakonda from...

3M ago

PTGX

Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target...

4M ago

PTGX

PTGX FAQ

What was Protagonist Therapeutics Inc’s price range in the past 12 months?

Protagonist Therapeutics Inc lowest stock price was $50.48 and its highest was $141.10 in the past 12 months.

What is Protagonist Therapeutics Inc’s market cap?

Protagonist Therapeutics Inc’s market cap is $9.06B.

When is Protagonist Therapeutics Inc’s upcoming earnings report date?

Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.

How were Protagonist Therapeutics Inc’s earnings last quarter?

Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.55.

Is Protagonist Therapeutics Inc overvalued?

According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics Inc pay dividends?

Protagonist Therapeutics Inc does not currently pay dividends.

What is Protagonist Therapeutics Inc’s EPS estimate?

Protagonist Therapeutics Inc’s EPS estimate is 2.14.

How many shares outstanding does Protagonist Therapeutics Inc have?

Protagonist Therapeutics Inc has 64,311,370 shares outstanding.

What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?

Protagonist Therapeutics Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went up 4.798%.

Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?

Currently, no hedge funds are holding shares in PTGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$125.00

▲(17.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"$49","166":"$166","78.25":"$78.3","107.5":"$107.5","136.75":"$136.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,78.25,107.5,136.75,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.17,128.23384615384614,131.2976923076923,134.36153846153846,137.42538461538462,140.48923076923077,143.55307692307693,146.6169230769231,149.68076923076924,152.74461538461537,155.80846153846153,158.8723076923077,161.93615384615384,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.17,125.15692307692308,125.14384615384616,125.13076923076923,125.11769230769231,125.10461538461539,125.09153846153846,125.07846153846154,125.06538461538462,125.05230769230769,125.03923076923077,125.02615384615385,125.01307692307692,{"y":125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.17,123.23384615384616,121.29769230769232,119.36153846153846,117.42538461538462,115.48923076923077,113.55307692307693,111.61692307692307,109.68076923076923,107.74461538461539,105.80846153846154,103.87230769230769,101.93615384615384,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.24,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.37,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.92,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >